Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer.
• Its development involves specific chromosomal rearrangements (17;22) creating the COL1A1-PDGFB fusion gene.

Purpose of the Study:

• To review the role of targeted therapy in DFSP management.
• To highlight imatinib's efficacy in advanced and difficult-to-treat DFSP cases.

Main Methods:

• Review of clinical trials and data on imatinib therapy for DFSP.
• Analysis of molecular pathogenesis and targeted treatment strategies.

Main Results:

• Imatinib, a tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in advanced DFSP.
• It is considered the gold standard for inoperable, metastatic, or recurrent DFSP.
• Imatinib can facilitate surgical resection and reduce disfigurement.

Conclusions:

• Targeted therapy with imatinib has transformed DFSP treatment.
• Imatinib offers a valuable option for patients with advanced or unresectable DFSP.
• Combination therapy (imatinib followed by surgery) can lead to disease eradication.